Proceeds to accelerate clinical development of best-in-class immunology programs and advance preclinical programs against novel drug targets with its prolific drug discovery engine
ENCINITAS, Calif., March 9, 2021 /PRNewswire/ — Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biotechnology company advancing a pipeline of immune modulators to treat inflammatory diseases and autoimmune disorders, today announced the completion of a $114 million equity financing led by venBio Partners alongside new investors, including Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, Cormorant Asset Management, and participation from founding investor New Science Ventures. In connection with the financing, Richard Gaster and Aaron Royston of venBio Partners and Jigar Choksey of Third Point will be joining the Ventyx Board of Directors.
“We are extremely proud to have the support of such prominent investors who share our enthusiasm, dedication and vision to build a world-class immunology company,” said Raju Mohan, Chief Executive Officer of Ventyx. “The additional capital will allow us to accelerate our clinical development programs while simultaneously expanding our portfolio of small molecule therapeutics with best-in-class potential for patients with inflammatory and autoimmune diseases. We have brought together a syndicate of experienced investors that can support the long-term growth and development of our deep pipeline of immune modulators.”
